Maria Kondrup1, Anneli Dowler Nygaard2, Jonna Skov Madsen3,4, Troels Bechmann1,3. 1. Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, 7100 Vejle, Denmark. 2. Department of Oncology, Aarhus University Hospital, 8000 Aarhus, Denmark. 3. Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, 5000 Odense, Denmark. 4. Biochemistry and Immunology, Lillebaelt Hospital, University Hospital of Southern Denmark, 7100 Vejle, Denmark.
Abstract
Brain metastases are frequent in patients with lung cancer and a major cause of morbidity and mortality. Finding a biomarker predicting brain metastases could facilitate early start of treatment and thereby reduce morbidity and possibly improve overall survival. Previous studies suggest S100B as a possible biomarker for this purpose. This prospective study enrolled 185 patients with newly diagnosed stage IV non-small cell lung cancer (NSCLC). A total of 22 patients had brain metastases verified by magnetic resonance imaging or computed tomography at the time of enrollment. Serum S100B levels were measured in blood samples collected prior to any treatment from 22 patients who had brain metastases at enrollment and from 50 patients randomly selected from the remaining 163 patients without brain metastases at enrollment. No statistically significant difference was found in the levels of serum S100B between patients with and without brain metastases [range 0.018-0.209 µg/l, mean 0.049 µg/l, 95% confidence interval (CI), 0.032-0.061 µg/l] and (range 0.016-0.130 µg/i, mean 0.044 µg/l, 95% CI, 0.037-0.051 µg/l), respectively, (P=0.852). Univariate analysis of prognostic factors for S100B indicated a correlation (P<0.2) with sex (P=0.088) and histology (adenocarcinoma vs. squamous cell carcinoma/others) (P=0.028). In the multivariate analysis only histology (P=0.029) remained statistically significant. Conclusion: The present study found no significant correlation between the level of serum S100B and the presence of brain metastases in patients with advanced NSCLC. The clear cut-off of S100B in patients with and without brain metastases reported in other studies could not be verified in this study. Further studies investigating the role of S100B as a biomarker for brain metastases in non-small cell lung cancer are warranted.
Brain metastases are frequent in patients with lung cancer and a major cause of morbidity and mortality. Finding a biomarker predicting brain metastases could facilitate early start of treatment and thereby reduce morbidity and possibly improve overall survival. Previous studies suggest S100B as a possible biomarker for this purpose. This prospective study enrolled 185 patients with newly diagnosed stage IV non-small cell lung cancer (NSCLC). A total of 22 patients had brain metastases verified by magnetic resonance imaging or computed tomography at the time of enrollment. Serum S100B levels were measured in blood samples collected prior to any treatment from 22 patients who had brain metastases at enrollment and from 50 patients randomly selected from the remaining 163 patients without brain metastases at enrollment. No statistically significant difference was found in the levels of serum S100B between patients with and without brain metastases [range 0.018-0.209 µg/l, mean 0.049 µg/l, 95% confidence interval (CI), 0.032-0.061 µg/l] and (range 0.016-0.130 µg/i, mean 0.044 µg/l, 95% CI, 0.037-0.051 µg/l), respectively, (P=0.852). Univariate analysis of prognostic factors for S100B indicated a correlation (P<0.2) with sex (P=0.088) and histology (adenocarcinoma vs. squamous cell carcinoma/others) (P=0.028). In the multivariate analysis only histology (P=0.029) remained statistically significant. Conclusion: The present study found no significant correlation between the level of serum S100B and the presence of brain metastases in patients with advanced NSCLC. The clear cut-off of S100B in patients with and without brain metastases reported in other studies could not be verified in this study. Further studies investigating the role of S100B as a biomarker for brain metastases in non-small cell lung cancer are warranted.
Authors: Michael A Vogelbaum; Thomas Masaryk; Peter Mazzone; Tarek Mekhail; Vincent Fazio; Sally McCartney; Nicola Marchi; Andrew Kanner; Damir Janigro Journal: Cancer Date: 2005-08-15 Impact factor: 6.860
Authors: Benjamin Weide; Sabina Richter; Petra Büttner; Ulrike Leiter; Andrea Forschner; Jürgen Bauer; Laura Held; Thomas Kurt Eigentler; Friedegund Meier; Claus Garbe Journal: PLoS One Date: 2013-11-28 Impact factor: 3.240
Authors: F K Holla; T J Postma; M A Blankenstein; T J M van Mierlo; M J Vos; E M Sizoo; M de Groot; B M J Uitdehaag; J Buter; M Klein; J C Reijneveld; J J Heimans Journal: J Neurooncol Date: 2016-07-11 Impact factor: 4.130
Authors: Matthias Preusser; Frank Winkler; Manuel Valiente; Christian Manegold; Elizabeth Moyal; Georg Widhalm; Jörg-Christian Tonn; Christoph Zielinski Journal: ESMO Open Date: 2018-01-26
Authors: Myrto Moutafi; Sandra Martinez-Morilla; Prajan Divakar; Ioannis Vathiotis; Niki Gavrielatou; Thazin Nwe Aung; Vesal Yaghoobi; Aileen I Fernandez; Jon Zugazagoitia; Roy S Herbst; Kurt A Schalper; David L Rimm Journal: J Thorac Oncol Date: 2022-04-28 Impact factor: 20.121